Omada Health Short Interest Hits Year High Before November Earnings

Short interest in OMDA has climbed to 14.5% of free float, its highest level in at least a year, rising 19% in a single week and 35% over the past month, while the stock slipped 1.7% to $19.01 against a median gain of roughly 2% for its closest peers.

The short-side build is the dominant story this week. Shares short crossed 8.39 million by October 27, up from around 7.1 million a week earlier. That step-change happened almost entirely between October 23 and 26, when short positions jumped by more than 1.1 million shares in two sessions. The ORTEX short score has tracked higher in parallel, moving from 54.3 on October 20 to 57.9 by October 27, a multi-week high. Despite the growing short base, the borrow market remains uncrowded: availability is running at 1,199%, meaning roughly twelve shares are available to borrow for every one already lent out. Cost to borrow is 0.38%, barely above the risk-free rate. This is not a squeeze setup. Shorts are adding with plenty of room to manoeuvre, and there is no friction in the lending pool that would force an unwind.

The Street remains constructive even as short sellers pile in. The consensus across covered analysts is positive, with a mean price target of $28.17 against a current price of $19.01, implying roughly 48% upside from here. After Omada's August earnings beat (the stock rallied 24% on the day and held most of that into the following week), JP Morgan raised its target to $30 and Barclays followed in September with a move to $27, both maintaining Overweight ratings. BTIG is the most bullish name on the sheet at $35. The bull case centres on the B2B2C model: selling through employers, health plans, and PBMs, Omada has over 90% customer retention, 33% of contracts now covering multiple products, and GLP-1-related billings growing 52% year-over-year. The bear case is structural: 66% of revenue runs through affiliated channels, the virtual care market is crowded, and profitability remains a work in progress despite operating leverage improving in Q1 2026. EV/EBITDA at 25.9x has compressed by about 1.1 turns over the past month, reflecting the slide in the share price rather than any earnings revision. The 90-day EPS momentum factor ranks in the 95th percentile, and the 12-month forward EPS growth rank sits at 87, so the earnings trajectory is not what's worrying short sellers.

The ownership picture adds a layer of context. BlackRock filed a fresh Schedule 13G on October 27, disclosing a 6.0% stake (3.67 million shares) for the first time, making it the most recent large-holder disclosure. American Century added 1.22 million shares in the quarter ending September 30, bringing its position to 6.2% of shares. Morgan Stanley added 1.33 million shares in the period to June 30. These are passive and long-only flows moving in the same direction as the short sellers, a split that reflects genuine disagreement about Omada's near-term path. No Schedule 13D activist is on the register. Casey Tansey, who held 8.2% at the IPO, has cut to 0.2% as of February 2026, and FMR has trimmed from 8.5% to 5.6%, so there has been meaningful distribution from early holders that may be part of what the short side is leaning on. Insider activity in the window carries limited signal: the October 5 director grants were compensation awards (type A), not open-market purchases, and the CEO's October 1 sales of roughly $357,000 were executed under a pre-arranged 10b5-1 plan.

The last two earnings prints produced outsized moves. The August 2026 result drove a 24% single-day gain and a 28% five-day move. The September 2026 print reversed that, with an 8.6% single-day loss. The next event is scheduled for November 5. With short interest at a year high, availability loose, and the prior print a sharp miss, the setup into that date is the specific thing to watch: whether the short build holds into the release or begins to unwind in the days before will say more about conviction on the short side than the current level alone.